home / stock / vir / vir articles
U.S. President Joe Biden is set to unveil a $100 million research initiative to tackle the growing threat of drug-resistant bacteria.&nbs...
BofA Securities has downgraded Vir Biotechnology Inc (NASDAQ: VIR) to Neutral from Buy with a price target of $14, down from $2...
U.S. stock futures traded lower this morning on Friday. Here are some big stocks recording losses in today’s pre-market trading session. Dig...
News, Short Squeeze, Breakout and More Instantly...
Fast Track designation follows positive preliminary Phase 2 trial data presented at the European Association for the Study of the Liver Congress 2024 and underscores the unmet need for people living with chronic hepatitis delta Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that ...
2024-06-05 19:15:02 ET Morgan Stanley analyst issues EQUAL-WEIGHT recommendation for VIR on June 5, 2024 05:15PM ET. The previous analyst recommendation was Equal-Weight. VIR was trading at $12.66 at issue of the analyst recommendation. The overall analyst consensus : BU...
2024-06-05 17:00:05 ET Michael Ulz from Morgan Stanley issued a price target of $15.00 for VIR on 2024-06-05 14:37:00. The adjusted price target was set to $15.00. At the time of the announcement, VIR was trading at $12.66. The overall price target consensus is at $30.13...